阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

未开盘 02-03 16:00:00 EST

184.32

-4.09

-2.17%

盘后186.00

+1.68+0.91%

19:40 EST

最高190.72	最低183.63	成交量265.97万
今开187.61	昨收188.41	日振幅3.76%
总市值2,859亿	流通市值2,846亿	总股本15.51亿
成交额4.98亿	换手率0.17%	流通股本15.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":184.32,"timestamp":1770152400000,"preClose":188.41,"halted":0,"volume":2659669,"hourTrading":{"tag":"盘后","latestPrice":186,"preClose":184.32,"latestTime":"19:40 EST","volume":3426,"amount":634418.7737,"timestamp":1770165652524,"change":1.68,"changeRate":0.009115,"amplitude":0.008084},"delay":0,"changeRate":-0.02170797728358369,"floatShares":1544000000,"shares":1551000000,"eps":3.009339,"marketStatus":"未开盘","change":-4.09,"latestTime":"02-03 16:00:00 EST","open":187.61,"high":190.72,"low":183.63,"amount":497866046.58562,"amplitude":0.037631,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.009339,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770195600000},"marketStatusCode":0,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NYSE","adjPreClose":188.41,"dividendRate":0.008491,"preHourTrading":{"tag":"盘前","latestPrice":187.68,"preClose":188.41,"latestTime":"09:29 EST","volume":24110,"amount":4550498.9777,"timestamp":1770128999832,"change":-0.73,"changeRate":-0.003875,"amplitude":0.012207},"postHourTrading":{"tag":"盘后","latestPrice":186,"preClose":184.32,"latestTime":"19:40 EST","volume":3426,"amount":634418.7737,"timestamp":1770165652524,"change":1.68,"changeRate":0.009115,"amplitude":0.008084},"volumeRatio":0.7874759050153508,"impliedVol":0.3209,"impliedVolPercentile":0.896},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2608824783","title":"Saphnelo皮下剂型申请遭FDA驳回，阿斯利康：承诺与FDA密切合作以尽快推进申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2608824783","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608824783?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:16","pubTimestamp":1770113773,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4568","BK4007","LU1829250122.USD","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","LU2236285917.USD","LU2462157665.USD","BK4588","LU2417539215.USD","BK4585","AZN","LU2456880835.USD"],"gpt_icon":0},{"id":"2608234829","title":"阿斯利康狼疮药自行注射剂型申请遭FDA驳回","url":"https://stock-news.laohu8.com/highlight/detail?id=2608234829","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608234829?lang=zh_cn&edition=full","pubTime":"2026-02-03 17:25","pubTimestamp":1770110748,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","LU1829250122.USD","LU2462157665.USD","AZN","BK4588","BK4568","LU2417539215.USD","LU0889565916.HKD","BK4585","LU0109394709.USD","LU2456880835.USD","LU2236285917.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2608294608","title":"股价一度跌近2%！阿斯利康(AZN.US)狼疮药自行注射剂型申请遭FDA驳回","url":"https://stock-news.laohu8.com/highlight/detail?id=2608294608","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608294608?lang=zh_cn&edition=full","pubTime":"2026-02-03 17:16","pubTimestamp":1770110175,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国食品药品监督管理局近日驳回了阿斯利康狼疮治疗药物的自行注射剂型上市申请，不过这家英国制药企业表示，目前仍在与监管机构沟通，推进该申请的审批进程。此次阿斯利康提交的为皮下注射剂型申请，若获批，患者可实现每周自行注射给药。阿斯利康方面披露，全球范围内受该疾病困扰的患者超340万人。据悉，FDA预计将在今年上半年对阿斯利康提交的补充申请作出审批决定，在此期间，该药物的静脉注射剂型仍正常供应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2462157665.USD","BK4585","AZN","LU2456880835.USD","LU2236285917.USD","LU0320765992.SGD","BK4007","LU2417539215.USD","LU0889565916.HKD","BK4588","LU0109394709.USD","LU1829250122.USD","BK4568"],"gpt_icon":0},{"id":"1136517370","title":"财报前瞻｜阿斯利康本季度营收预计增8.99%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1136517370","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136517370?lang=zh_cn&edition=full","pubTime":"2026-02-03 10:00","pubTimestamp":1770084035,"startTime":"0","endTime":"0","summary":"阿斯利康将在2026年02月10日发布最新季度财报，市场关注肿瘤与罕见病业务的延续增长与盈利质量的变化。市场一致预期本季度总收入为155.11亿美元，同比增加8.99%；EBIT为47.13亿美元，同比增加12.06%；调整后每股收益为1.03美元，同比下降1.91%。围绕利润率指标，当前一致预期未提供毛利率与净利率的本季度具体预测；公司上季度财报未给出本季度毛利率或净利率的明确预估。根据近期机构观点的汇总，市场对阿斯利康的立场偏向看多。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜阿斯利康本季度营收预计增8.99%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"gpt_icon":0},{"id":"2608852370","title":"加码美国市场：阿斯利康登陆纽交所，伦敦地位或被削弱","url":"https://stock-news.laohu8.com/highlight/detail?id=2608852370","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608852370?lang=zh_cn&edition=full","pubTime":"2026-02-02 19:59","pubTimestamp":1770033595,"startTime":"0","endTime":"0","summary":"公司表示，此举将使其在英国、瑞典和美国的上市地位具有同等分量。此后，美国投资者将更容易购买阿斯利康的完整股票，这增加了该公司在伦敦上市地位相关性可能下降的可能性。在美国总统特朗普关税计划带来的压力下，阿斯利康承诺到2030年在美国投资500亿美元。阿斯利康的 ADR 交易量在截至2024年的五年间增长了34%，而同期伦敦股市的成交量增长不足8%。","market":"us","thumbnail":"https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400590.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加码美国市场：阿斯利康登陆纽交所，伦敦地位或被削弱","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2462157665.USD","LU1829250122.USD","BK4585","LU2236285917.USD","LU2417539215.USD","AZN","BK4568","BK4588","LU2456880835.USD","LU0889565916.HKD"],"gpt_icon":1},{"id":"2608833532","title":"中金：石药集团(01093)与阿斯利康达成重磅合作 维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2608833532","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608833532?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:37","pubTimestamp":1769996220,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持石药集团“跑赢行业”评级，考虑对外授权持续兑现上调目标价9.1%到12港元。石药集团公告与阿斯利康签订研发合作与授权协议。中金主要观点如下：中国创新药授权出海再获里程碑式突破根据公告，石药集团及附属公司授权阿斯利康在全球范围内独家开发、生产和商业化8个创新长效多肽药物项目，阿斯利康将支付合计12亿美元预付款以及后续累计最高35亿/138亿美元的开发/销售里程碑款项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01093","AZN"],"gpt_icon":0},{"id":"2607604639","title":"阿斯利康全球CEO：中国在全球医药创新生态中不可或缺","url":"https://stock-news.laohu8.com/highlight/detail?id=2607604639","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607604639?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:16","pubTimestamp":1769779009,"startTime":"0","endTime":"0","summary":"中新社北京1月30日电(记者尹倩芸迟瀚宇)阿斯利康全球首席执行官苏博科(PascalSoriot)30日在北京接受中新社记者采访时表示，中国已成为全球医药创新生态中不可或缺的组成部分。阿斯利康近日宣布，计划于2030年前在中国投资逾1000亿元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303637319957.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303637319957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2417539215.USD","AZN","BK4007","LU0320765992.SGD","LU2456880835.USD","159938","BK1574","LU2462157665.USD","LU1829250122.USD","BK1515","BK4568","LU2236285917.USD","BK1161","BK4588","BK4585","LU0889565916.HKD","09939","LU0109394709.USD"],"gpt_icon":0},{"id":"2607905074","title":"石药集团(01093)与阿斯利康就创新长效多肽药物开发签订战略合作与授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2607905074","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607905074?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:11","pubTimestamp":1769731893,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团已与全球生物制药领导者阿斯利康签订战略研发合作与授权协议，以利用集团专有的缓释给药技术平台及多肽药物AI发现平台，开发创新长效多肽药物。同时，集团的多肽药物AI发现平台可以针对药物靶点快速设计及筛选候选分子，并可在药效、选择性与信号偏向性等维度进行系统优化。根据该协议的条款，集团将与阿斯利康在创新多肽分子的发现和长效递送产品的开发方面开展全面战略合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0880133367.SGD","IE00BZ08YR35.GBP","LU1226287875.USD","LU1993786604.SGD","LU1226288170.HKD","LU1960683339.HKD","LU2456880835.USD","BK4568","LU0067412154.USD","LU1226287529.USD","IE00B031HY20.USD","LU0320765992.SGD","01093","LU1226287792.SGD","IE00B543WZ88.USD","LU1008478684.HKD","BK1191","LU0501845795.SGD","SG9999004220.SGD","LU0889565916.HKD","HK0000165453.HKD","BK1515","LU1951186391.HKD","LU2039709279.SGD","LU0109394709.USD","IE0008368742.USD","BK1521","LU2462157665.USD","LU1328277881.USD","BK4007","LU1807302812.USD","BK4585","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","LU2236285917.USD","LU0314109678.HKD","IE0008369823.USD","LU1152091168.USD","LU0072913022.USD","LU0326950275.SGD","LU1813983027.USD","BK4588","IE00B5MMRT66.SGD","LU1226288253.USD","LU0140636845.USD","LU0315179316.USD","AZN","LU1829250122.USD","LU2417539215.USD","LU1152091754.HKD"],"gpt_icon":0},{"id":"2607082557","title":"【财闻联播】阿斯利康：将在华投资逾1000亿元！多只黄金股提示风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2607082557","media":"券商中国","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607082557?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:11","pubTimestamp":1769688660,"startTime":"0","endTime":"0","summary":"报告期内，财富管理、资产管理、投资交易等业务收入实现同比增长，公司整体经营业绩显著提升。若该基金2026年2月2日二级市场交易价格溢价幅度未有效回落，基金有权通过向深圳证券交易所申请盘中临时停牌、延长停牌时间等措施，向市场警示风险，具体以届时公告为准。阿斯利康将于2030年前在华投资逾1000亿元　　阿斯利康今日宣布，计划于2030年前在中国投资逾1000亿元人民币，以扩大在药品生产与研发领域的布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-29/doc-inhiyrwi1005758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4568","BK4007","LU1829250122.USD","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","LU2236285917.USD","LU2462157665.USD","BK4588","LU2417539215.USD","159562","BK4585","AZN","LU2456880835.USD"],"gpt_icon":0},{"id":"2607088305","title":"阿斯利康宣布到2030年将在中国投资150亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607088305","media":"第一财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607088305?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:59","pubTimestamp":1769680778,"startTime":"0","endTime":"0","summary":"【阿斯利康宣布到2030年将在中国投资150亿美元】英国制药公司阿斯利康宣布，到2030年将在中国投资150亿美元，用于扩大研发和生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601293635388560.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635388560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2462157665.USD","LU1829250122.USD","BK4585","LU2236285917.USD","LU2417539215.USD","AZN","LU0320765992.SGD","BK4568","LU0109394709.USD","BK4588","LU2456880835.USD","LU0889565916.HKD","BK4007"],"gpt_icon":0},{"id":"2607700539","title":"英国首相斯塔默：阿斯利康在中国的投资将帮助该公司持续增长，并支持数以千计的英国就业岗位。","url":"https://stock-news.laohu8.com/highlight/detail?id=2607700539","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607700539?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:50","pubTimestamp":1769680249,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2456880835.USD","LU0889565916.HKD","AZN","BK4588","LU0109394709.USD","LU1829250122.USD","BK4007","BK4585","LU2236285917.USD","LU0320765992.SGD","LU2417539215.USD","BK4568","LU2462157665.USD"],"gpt_icon":0},{"id":"2607700532","title":"阿斯利康：到2030年，将在中国投资150亿美元，以扩大研发和制造业务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2607700532","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607700532?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:50","pubTimestamp":1769680218,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0320765992.SGD","LU2462157665.USD","BK4588","BK4007","LU2456880835.USD","BK4585","LU0889565916.HKD","AZN","LU2236285917.USD","LU1829250122.USD","LU2417539215.USD","BK4568","LU0109394709.USD"],"gpt_icon":0},{"id":"2606088432","title":"花旗：予阿斯利康“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2606088432","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606088432?lang=zh_cn&edition=full","pubTime":"2026-01-27 14:26","pubTimestamp":1769495173,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4568","LU2417539215.USD","BK4566","LU0477156953.USD","LU0889565916.HKD","BK4007","LU1829250122.USD","LU0128525689.USD","LU1668664300.SGD","LU0130102774.USD","LU2456880835.USD","IE00BSNM7G36.USD","LU0320765646.SGD","LU1791807156.HKD","LU0980610538.SGD","LU0106831901.USD","LU2236285917.USD","LU2462157665.USD","BK4559","LU1244550494.USD","LU0648001328.SGD","LU0320765992.SGD","LU0109394709.USD","BK4504","LU0310800965.SGD","LU1267930227.SGD","BK4588","LU1201861249.SGD","LU1244550577.SGD","BK4207","LU1162221912.USD","LU2125154935.USD","BK4534","LU0170899867.USD","LU1366192091.USD","LU0130517989.USD","LU0098860793.USD","LU1244550221.USD","LU2360032135.SGD","BK4585","AZN","LU0162691827.USD","LU2125154778.USD","LU0072461881.USD","LU0052756011.USD"],"gpt_icon":0},{"id":"2606208876","title":"阿斯利康告别纳斯达克，统一全球上市平台，地缘政策与价值重估的双重考量","url":"https://stock-news.laohu8.com/highlight/detail?id=2606208876","media":"华夏时报网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606208876?lang=zh_cn&edition=full","pubTime":"2026-01-27 14:22","pubTimestamp":1769494936,"startTime":"0","endTime":"0","summary":"2026年1月20日，英国制药巨头阿斯利康宣布，将自愿从纳斯达克退市其美国存托凭证及债务证券，相关调整将于1月30日收盘后正式生效。从2月2日起，这家全球领先的生物制药企业将在纽约证券交易所开始交易其普通股及债券，股票代码仍为“AZN”。这不是一次简单的交易所转移，而是阿斯利康构建“统一上市结构”的关键一步。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601273632092534.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601273632092534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AZN","LU2236285917.USD","BK4568","USAW.SI","MNQmain","QYLD","GPIQ","SQQQ","TSYW.SI","BK4007","QID","LU0889565916.HKD","PSQ","BK4588","LU1829250122.USD","LU0320765992.SGD","LU2462157665.USD","TQQQ","LU2417539215.USD","QYLG","QLD","USJW.SI","QQQE","JEPQ","NVIW.SI","BK4585","QQQJ","LU0109394709.USD","LU2456880835.USD","QQQY","BK1147","NQmain"],"gpt_icon":1},{"id":"2606213404","title":"阿斯利康中国(AZN)：舒立瑞在华获批用于治疗6岁及以上儿童难治性全身型重症肌无力患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2606213404","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606213404?lang=zh_cn&edition=full","pubTime":"2026-01-26 17:12","pubTimestamp":1769418767,"startTime":"0","endTime":"0","summary":"金吾财讯 |据阿斯利康中国(AZN)消息，中国国家药品监督管理局已正式批准舒立瑞®（英文商品名： Soliris®，通用名：依库珠单抗注射液），适应症扩展至用于治疗6岁及以上抗乙酰胆碱受体（AChR）抗体阳性的难治性全身型重症肌无力（gMG）儿童患者。gMG是一种罕见的、致残性、慢性自身免疫性神经肌肉疾病，可导致肌肉功能丧失和严重衰弱。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"296558","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2417539215.USD","LU0109394709.USD","LU2456880835.USD","BK4007","LU2462157665.USD","BK4568","BK4588","LU0320765992.SGD","LU2236285917.USD","LU1829250122.USD","BK4585","LU0889565916.HKD","AZN"],"gpt_icon":0},{"id":"2605429045","title":"第一三共/阿斯利康(AZN.US)“德曲妥珠单抗”在华获批治疗HER2阳性胃癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2605429045","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605429045?lang=zh_cn&edition=full","pubTime":"2026-01-23 14:45","pubTimestamp":1769150736,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月22日，第一三共/阿斯利康共同宣布，注射用德曲妥珠单抗正式获得中国国家药品监督管理局批准，单药用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。据悉，该适应症是德曲妥珠单抗在华获批的第六个适应症，也是HER2阳性胃癌相关的第二个适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109394709.USD","BK4007","BK4588","BK4585","LU0889565916.HKD","LU2417539215.USD","LU1829250122.USD","AZN","LU0320765992.SGD","LU2456880835.USD","LU2462157665.USD","BK4568","LU2236285917.USD"],"gpt_icon":0},{"id":"2605290194","title":"阿斯利康(AZN.US)宣布PD-L1单抗在华获批新适应症 针对子宫内膜癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2605290194","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605290194?lang=zh_cn&edition=full","pubTime":"2026-01-23 14:42","pubTimestamp":1769150545,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月22日，阿斯利康宣布，英飞凡已获中国国家药品监督管理局批准，与卡铂和紫杉醇联合用于错配修复缺陷的原发晚期或复发性子宫内膜癌成人患者的一线治疗，随后以本品单药维持治疗。截至目前该药已在美国获批 10 项适应症，在欧盟获批 11 项适应症，在国内获批 7 项。安全性方面，度伐利尤单抗联合化疗方案的总体安全性和耐受性良好，并且与此前临床试验结果总体一致，没有出现新的安全信号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU0320765992.SGD","LU0889565916.HKD","BK4588","LU1829250122.USD","BK4568","LU0109394709.USD","LU2456880835.USD","BK4023","AZN","LU1169589451.USD","LU1169590202.USD","LU2417539215.USD","BK4007","LU2462157665.USD","LU2236285917.USD","PD"],"gpt_icon":0},{"id":"2605495703","title":"优赫得®在华获批治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495703","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605495703?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:38","pubTimestamp":1769078280,"startTime":"0","endTime":"0","summary":"研究显示，对于局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者，与雷莫西尤单抗+紫杉醇相比，德曲妥珠单抗带来具有显著统计学差异和临床意义的总生存期改善。自一年多前首次在中国获批用于HER2阳性局部晚期或转移性胃癌以来，德曲妥珠单抗仅可用于三线及后线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4868984_ZH68984_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4560","LU2462157665.USD","LU2237443382.USD","LU1244550494.USD","LU0320765992.SGD","LU0792757196.USD","IE000M9KFDE8.USD","BK4080","LU2506951958.HKD","LU0109394709.USD","LU2237443549.SGD","LU0868494617.USD","OS","IE00BKVL7J92.USD","LU2237443895.HKD","LU2506952097.USD","LU1221951046.USD","LU1196500208.SGD","SG9999015945.SGD","CSCO","SG9999001440.SGD","LU1880398471.USD","SG9999015978.USD","AZN","BK4527","LU1571399168.USD","BK4195","LU1046421795.USD","LU1066051498.USD","LU1066053197.SGD","LU1244550577.SGD","BK4585","LU1929549753.HKD","LU2247934214.USD","LU2417539215.USD","PFS","BK4612","LU1221951129.SGD","IE00BFMHRM44.USD","BK4097","LU0234572021.USD","LU2506951875.HKD","ADC","LU1894683348.USD","ORR","LU2237443622.USD","BK4588","BK4579","BK4231","LU1880398554.USD"],"gpt_icon":0},{"id":"2604167035","title":"阿斯利康将从纳斯达克转板到纽交所直接上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2604167035","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604167035?lang=zh_cn&edition=full","pubTime":"2026-01-20 15:33","pubTimestamp":1768894380,"startTime":"0","endTime":"0","summary":"英国制药巨头阿斯利康公司周二表示，将从纳斯达克交易所摘除其美国存托股票和债券，并于 2026 年 1 月 30 日股市收盘后完成其普通股和债券在纽约证券交易所的直接上市。　　这一举措是经阿斯利康股东批准的一项计划的一部分，旨在统一公司的股票上市结构，使投资者能够在伦敦证券交易所、纳斯达克斯德哥尔摩交易所和纽约证券交易所之间交易其普通股。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-01-20/doc-inhhxvez7499886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["JEPQ","QYLG","LU0320765992.SGD","LU2462157665.USD","NVIW.SI","QQQY","QQQJ","LU0109394709.USD","LU1829250122.USD","QQQE","USAW.SI","USJW.SI","MNQmain","LU2417539215.USD","LU2236285917.USD","QLD","LU2456880835.USD","SQQQ","QYLD","QID","QQQ","BK4007","TSYW.SI","AZN","BK4588","QQQM","GPIQ","BK1147","LU0889565916.HKD","TQQQ","BK4585","PSQ","BK4568"],"gpt_icon":0},{"id":"2604216257","title":"阿斯利康：将在纽约证券交易所完成直接上市。","url":"https://stock-news.laohu8.com/highlight/detail?id=2604216257","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604216257?lang=zh_cn&edition=full","pubTime":"2026-01-20 15:07","pubTimestamp":1768892829,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["AZN","LU2462157665.USD","LU2236285917.USD","LU1829250122.USD","BK4588","LU0109394709.USD","LU0889565916.HKD","BK4007","LU2456880835.USD","BK4585","BK4568","LU2417539215.USD","LU0320765992.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.036},{"period":"1month","weight":0.0064},{"period":"3month","weight":0.1357},{"period":"6month","weight":0.2359},{"period":"1year","weight":0.3192},{"period":"ytd","weight":0.0025}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.393939,"avgChangeRate":-0.016809},{"month":3,"riseRate":0.5625,"avgChangeRate":0.027992},{"month":4,"riseRate":0.65625,"avgChangeRate":0.031251},{"month":5,"riseRate":0.53125,"avgChangeRate":0.008752},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018334},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.002513},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NYSE","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}